company background image
EXEL

Exelixis NasdaqGS:EXEL Stock Report

Last Price

US$16.79

Market Cap

US$5.4b

7D

-0.2%

1Y

-0.7%

Updated

28 Nov, 2022

Data

Company Financials +
EXEL fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance4/6
Financial Health6/6
Dividends0/6

EXEL Stock Overview

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States.

Exelixis, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Exelixis
Historical stock prices
Current Share PriceUS$16.79
52 Week HighUS$23.40
52 Week LowUS$14.87
Beta0.69
1 Month Change0.96%
3 Month Change-6.04%
1 Year Change-0.71%
3 Year Change0.54%
5 Year Change-39.10%
Change since IPO10.55%

Recent News & Updates

Recent updates

Is Exelixis (NASDAQ:EXEL) Using Too Much Debt?

Feb 20
Is Exelixis (NASDAQ:EXEL) Using Too Much Debt?

This Just In: Analysts Are Boosting Their Exelixis, Inc. (NASDAQ:EXEL) Outlook for This Year

Aug 10
This Just In: Analysts Are Boosting Their Exelixis, Inc. (NASDAQ:EXEL) Outlook for This Year

Did You Miss Exelixis' (NASDAQ:EXEL) Whopping 502% Share Price Gain?

Mar 14
Did You Miss Exelixis' (NASDAQ:EXEL) Whopping 502% Share Price Gain?

Have Exelixis, Inc. (NASDAQ:EXEL) Insiders Been Selling Their Stock?

Feb 21
Have Exelixis, Inc. (NASDAQ:EXEL) Insiders Been Selling Their Stock?

Shareholder Returns

EXELUS BiotechsUS Market
7D-0.2%0.2%0.3%
1Y-0.7%-16.1%-20.5%

Return vs Industry: EXEL exceeded the US Biotechs industry which returned -16.1% over the past year.

Return vs Market: EXEL exceeded the US Market which returned -20.5% over the past year.

Price Volatility

Is EXEL's price volatile compared to industry and market?
EXEL volatility
EXEL Average Weekly Movement4.2%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: EXEL is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: EXEL's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1994954Mike Morrisseyhttps://www.exelixis.com

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.

Exelixis, Inc. Fundamentals Summary

How do Exelixis's earnings and revenue compare to its market cap?
EXEL fundamental statistics
Market CapUS$5.42b
Earnings (TTM)US$307.62m
Revenue (TTM)US$1.64b

17.6x

P/E Ratio

3.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
EXEL income statement (TTM)
RevenueUS$1.64b
Cost of RevenueUS$54.91m
Gross ProfitUS$1.58b
Other ExpensesUS$1.28b
EarningsUS$307.62m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.95
Gross Margin96.65%
Net Profit Margin18.78%
Debt/Equity Ratio0%

How did EXEL perform over the long term?

See historical performance and comparison